Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Equivalent Dosing of Spironolactone and Eplerenone

Dosing Equivalence and Clinical Applications

  • The equivalent dosing ratio between spironolactone and eplerenone is approximately 1:2, with 25 mg of spironolactone being equivalent to 50 mg of eplerenone in terms of mineralocorticoid receptor antagonism 1, 2
  • The standard maintenance dose of spironolactone is 25-50 mg once daily, which is equivalent to eplerenone 50-100 mg once daily 2, 3
  • In heart failure treatment, the target dose for both medications is spironolactone 50 mg once daily or eplerenone 50 mg once daily 1, 4
  • Initial dosing typically starts at spironolactone 25 mg daily or eplerenone 25 mg daily, with subsequent titration based on clinical response and laboratory parameters 2, 5
  • For patients with renal impairment (eGFR 30-49 mL/min/1.73 m²), the starting dose should be reduced to spironolactone 12.5-25 mg once daily or eplerenone 25 mg every other day 2

Side Effect Profiles and Considerations

  • Spironolactone is associated with significant rates of gynecomastia in men (10-21% vs. 4.5% with eplerenone) 1
  • Eplerenone is specifically indicated as an alternative when patients develop breast discomfort or enlargement on spironolactone 1, 3
  • Both medications carry similar risks of hyperkalemia and renal dysfunction, requiring the same monitoring protocols 2

Monitoring Requirements

  • Check renal function and serum electrolytes before initiation 1, 2
  • Recheck renal function and electrolytes at 1 and 4 weeks after starting treatment 3, 5
  • Monitor monthly for the first 3 months, then every 3-6 months thereafter 6, 5
  • Discontinue or reduce dosage if potassium rises above 5.5 mmol/L 1, 4 or creatinine exceeds 2.5 mg/dL in men or 2.0 mg/dL in women 2, 4

Clinical Pearls

  • Both medications should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or baseline potassium >5.0 mmol/L 2, 4
  • The routine triple combination of ACE inhibitors, ARBs, and aldosterone antagonists should be avoided due to increased risk of hyperkalemia 6, 5

REFERENCES